NRC FORM 591M PART 1			S. NUCLEAR REGULAT			
(10-2003)	•		CHI COMMISSION			
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION						
1. LICENSEE/LOCATION INSPECTED:		2. NRC/REGIONAL OFFICE U.S. Nuclear Regulatory Commission				
North Kansas City Hospital 2800 Clay Edwards Drive	Region III 2443 Warrenville Road					
North Kansas City, MO 64116		Suite 210				
REPORT 2006-001 &-002		Lisle, Illinois 60532-4351				
3. DOCKET NUMBER(S)	4. LICENSEE NUM	BER(S)	5. DATE(S) OF I	NSPECTION		
030-13966	24-18628-01		March 7, 2006			
LICENSEE: The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows: 1. Based on the inspection findings, no violations were identified. 2. Previous violation(s) closed. 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.						
Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):						
4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)						
10 CFR 35.67(b)(2) requires sealed somes to be kited for leakage at						
3 year intervals (as approved by the commission).						
Confront to the above, the license did not test & cesium 3M model						
Contrary to the above, the license did not test & cesium 3M model COGC-CA sources for leakage at 3 year intervals. Specially the licensel						
LUGL-LA sources to many - cluder a strong erander than 3 man						
last rested the 311 sources on spinor, on instan grand from sycant						
The transee committed to teak test the sources ASAP.						
Licensee's Statement of Corrective Actions for Item 4, above.						
I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken,						
date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested,						
LICENSEE'S	ed Name	- B A Sign	ature	Date		
REPRESENTATI HAHAMEL	12408	1 Wala		3.7-06		
NRC INSPECTOR Deborah A. Pisku	ra	ARthura		3107106		
NHC FORM 591M PART 1 (10-2003)						

NRC FORM 591M PAR	ат з			U.S. NUCLEAR REGULATORY			
(10-2003)			COMMISSION				
10 CFR 2 201 Docket File Information							
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION							
1. LICENSEE			2. NRC/REGIONAL OFFICE				
North Kansas City Hospital		Region III 2443 Warrenville Road, Suite 210					
REPORT 2006-001 & 2006-002 Lisle, IL 60532							
		4. LICENSE NUMBER(S) 24-18628-01		5. DATE(S) OF INSPECTION Mar 7, 2006			
		7 INSPECTION FOCUS A 03.01, 03.02, 03.	ION FOCUS AREAS 03.02, 03.03, 03.04, 03.05, 03.06, 03.07, and 03.08				
SUPPLEMENTAL INSPECTION INFORMATION							
	G 2	3. LICENSEE CONTACT Kenneth W. Arne		4. TELEPHONE NUMBER 816.271.6000			
X Main Office Insp	pection		Next Inspection Date:	Feb. 2008			
X Field 275	50 Clay Edwards	Drive (Radiation On	cology) N.K.C., MO				
Temporary Job	Site						
		PROGRA					
This licensee was a 400-bed hospital, authorized to use licensed material permitted by Sections 35.100, 35.200, 35.300, 35.400, and 35.1000 Sr-90 IVB devices. The nuclear medicine department was staffed with seven full-time technologists who performed approximately 500-600+ diagnostic nuclear medicine procedures per month. Nuclear medicine activities were performed in two separate areas within the main hospital (diagnostic studies within the radiology department, and cardiac studies in the cardiac department). In addition, the hospital was authorized to perform cardiac imaging at a separate cardiac clinic (this program was inactive at the time of this inspection). The licensee received unit doses from a licensed radiopharmacy. The hospital performed a full spectrum of nuclear diagnostic imaging studies. Typically, in a year the hospital administered 20 iodine-131 thyroid carcinoma therapies and 20-25 hyperthyroidism treatments. The hospital obtained its I-131 in capsule form only. The department administered 4-5 Sr-89 and Sm-153 dosages annually for treatment of metastatic bone disease. Occasionally the department administered Bextar and Zevalin treatments. The licensee retained the services of a consulting physicist to audit the radiation safety program on a quarterly basis. The radiation therapy activities were performed by a contract medical physicist and one in-house dosimetrist. Brachytherapy activities included Pd-103 permanent implants and Cs-137/Ir-192 temporary gynecological implants (1-2 cases annually). Although the licensee was approved for 35.1000 material, the hospital transferred its IVB unit to the manufacturer for disposal.							
This inspection consisted of interviews with licensee personnel, a review of selected records, tours of the nuclear medicine and radiation oncology departments, and independent measurements. The inspector observed licensee nuclear medicine personnel prepare, assay and administer several unit doses for various imaging procedures. The inspection included observations of dose calibrator QA checks, package receipts and surveys, and area surveys. One violation of NRC requirements was identified concerning the licensee's failure to conduct sealed source leak tests on the Cs-137 brachytherapy sources at the approved 3-year intervals, as required by Section 35.67(b)(2). The last leak tests were performed on 8/17/2001 with the next tests due in August 2004. The licensee used its Cs-137 sources to treat three patients in late 2004 and 2005, however the hospital staff failed to recognize that the sources had not been tested prior to the administration of these implants. The licensee committed to perform the required leak tests on the brachytherapy sources ASAP and add a reminder to the department calender.							

NRC FORM 591M PART 3 (10-2003)